There was plenty of hype and hope attached to the arrival of Spravato (esketamine nasal spray) as a treatment for depression when it first started to be launche 10 July 2023
The US Food and Drug Administration (FDA) has converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer's Disease, to traditional app 7 July 2023
Eisai has broken new ground in the development of Alzheimer's treatments, gaining the first approval for decades. In the runup to AAIC 2023, we discuss progress 6 July 2023
Industry analyst GlobalData has provided a downbeat analysis of prospects for BioXcel following claims of “bad clinical practice” related to the TRANQUILITY II 3 July 2023
BlueRock Therapeutics, a wholly-owned subsidiary of German life sciences company Bayer, can boast that bemdaneprocel, its neuronal stem cell therapy for Parkins 28 June 2023
Swiss pharma giant Roche will not begin any new trials of rugonersen (RO7248824) in Angelman syndrome, a rare genetic condition that affects the nervous system 26 June 2023
Belgo-Dutch autoimmune diseases specialist argenx can now boast that it has the first subcutaneous (SC) injectable for generalized myasthenia gravis (gMG) to be 21 June 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.